Number of shares and votes in BioArctic AB (publ) as of December 29, 2023 December 29, 2023 18:30 Regulatory Read more
LEQEMBI® to be launched in Japan for Alzheimer’s disease on December 20 December 13, 2023 03:05 Regulatory Read more
Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today November 7, 2023 09:15 Regulatory Read more
LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period November 7, 2023 04:40 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of September 29, 2023 September 29, 2023 18:00 Regulatory Read more
“LEQEMBI® Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan September 25, 2023 07:00 Regulatory Read more
FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer’s disease July 7, 2023 02:00 Regulatory Read more
FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer’s disease June 10, 2023 01:00 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of May 31, 2023 May 31, 2023 18:00 Regulatory Read more
Correction of press release: BioArctic repurchases employee stock options from CEO May 16, 2023 20:30 Regulatory Read more
FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease and grants Priority Review March 6, 2023 00:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 28, 2023 February 28, 2023 18:00 Regulatory Read more
The Nomination Committee’s proposal for the election of Board members and Chairman of the Board in BioArctic AB February 6, 2023 08:30 Regulatory Read more
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease January 27, 2023 00:30 Regulatory Read more
BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election January 19, 2023 09:50 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in Japan January 16, 2023 01:30 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in the EU January 11, 2023 00:30 Regulatory Read more
FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer’s disease January 6, 2023 20:30 Regulatory Read more
